Select region:

Clinical trials located in

Villejuif

Villejuif city is located in France. Currently, 20 clinical trials are being conducted in this city.

Villejuif, located in the southern suburbs of Paris, France, is a city rich in history and cultural diversity. Established in the Middle Ages, its name, meaning “Jewish town,” hints at its historical Jewish community. Villejuif is renowned for hosting the Gustave Roussy Institute, one of Europe’s largest cancer research facilities. The city also boasts a vibrant arts scene, with the Maison d’Art Contemporain Chaillioux showcasing contemporary art. Villejuif’s green spaces, like the Hautes-Bruyères State Park, offer residents and visitors a natural retreat within the urban landscape.

  • CT-EU-00112395

    Study of belzutifan for treating advanced cancers

    This clinical trial aim is to test out a new drug called belzutifan, also known as MK-6482 or WELIREG™. It’s a pill patient can take once a day, and the main goal is to see if it can shrink or get rid of tumors in folks with certain types of cancer.

    The cancers the researchers are looking at are pheochromocytoma and paraganglioma, which are tumors that start in the adrenal glands or nervous system. Pancreatic neuroendocrine tumors, tumors related to von Hippel-Lindau disease, advanced gastrointestinal stromal tumors, and other solid tumors with certain genetic changes that involve a protein called HIF-2α, there will be also tested.

    The big thing the researchers are  keeping an eye on is the objective response rate, which means how many folks see their tumors shrink or disappear completely while taking this drug. The researchers will be watching closely for any side effects too, of course, to make sure this new medicine is safe.

    DenmarkFranceGermanyHungaryItalyNetherlandsSpainSwedenUnited Kingdom
  • To study the effectiveness of mitotane in preventing cancer recurrence in patients with adrenocortical carcinoma

    The ADIUVO trial is focused on understanding the effectiveness of a treatment called mitotane in patients who have undergone surgery for a rare type of adrenocortical cancer. This cancer has a high chance of coming back after surgery, and previous research suggests that mitotane may help reduce this risk. However, it is important to confirm these results in a study in which patients are randomly assigned to receive mitotane or no additional treatment after surgery. This is particularly important for patients whose cancer is at low or intermediate risk of coming back because doctors need to be sure that the benefits of mitotane outweigh any side effects.

    In this study, the goal is to see if mitotane can help patients live longer without their cancer coming back. Doctors will also assess patients’ overall life expectancy, quality of life and any side effects that may occur as a result of treatment. In addition, they will check whether mitotane levels in the blood influence these results and whether there are differences in results depending on certain characteristics of the cancer.

    Treatment with mitotane will be started at a lower dose and gradually increased depending on your tolerability, with adjustments possible depending on blood levels and side effects. The main goal is to compare how long patients remain cancer-free after surgery, with particular emphasis on their overall well-being and any potential side effects of treatment.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • CT-EU-00091258

    Study of Idasanutlin in combination with chemotherapy or other drugs in acute leukemia patients

    This study involves testing a new medication, Idasanutlin, for patients with recurrent or challenging-to-treat leukemias or solid tumors. In certain cases, the new medication will be administered in combination with other anti-cancer drugs, either traditional chemotherapy medications or Venetoclax. The primary objective is to assess the medication for potential side effects and its effectiveness in treating the disease. Initially, efforts will focus on determining a safe and well-tolerated dose for the new medication. Subsequently, the study will further investigate the safety and initial effectiveness of combining this drug with others in three groups: neuroblastoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

  • Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    BelgiumFranceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Studying immunoradiotherapy for metastatic tumors

    This clinical trial is all about improving the health of people who have metastatic solid tumors – that is, tumors that have started to spread to other parts of the body. The trial consists of two phases. In the initial phase, the goal is to determine the optimal safe dosage for use. Subsequently, in phase two, a comparison will be made between two treatment approaches to identify the more effective option. These include (1) radiotherapy combined with a medication known as GEN1042, and (2) radiotherapy with both GEN1042 and another drug called pembrolizumab. Vigilant monitoring will be maintained to assess the body’s response, with a primary focus on tumor responsiveness and potential side effects. The trial aims to enhance comprehension of tumor growth or reduction and overall participant health.

    France
  • Advanced colon cancer treatment trial using ompenaclid

    This study explores a new treatment approach for advanced colorectal cancer by combining ompenaclid with standard chemotherapy (FOLFIRI and bevacizumab). It aims to improve outcomes for patients with RAS mutant tumors. Participants receive either ompenaclid or a placebo alongside standard chemotherapy. The study focuses on tumor response and overall survival, hoping to provide a more effective treatment option for those battling this challenging form of cancer.

    BelgiumFranceSpain
  • Study of trastuzumab deruxtecan in gastric cancer or gastroesophageal junction adenocarcinoma

    The aim of the DESTINY-Gastric04 study is to help cancer patients suffering from certain diseases. These patients have a specific type of stomach cancer or adenocarcinoma of the gastroesophageal junction that has not responded to treatment or has gotten worse after treatment with a medicine called trastuzumab. This study is testing a new drug called trastuzumab deruxtecan, comparing it with a combination of two other drugs – ramucirumab and paclitaxel. A key goal of this study is to determine how long participants will live after starting a new treatment. It will also be observed whether the cancer will shrink or stop growing, how long it will last, what the potential side effects of treatment will be and how the body will respond to the new drug.

    BelgiumFranceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Testing glofitamab alone and with chemoimmunotherapy for young B-Cell Lymphoma patients

    This clinical trial concerns a medicine called glofitamab in kids and young adults who have a severe kind of blood cancer called Mature B-Cell Non-Hodgkin Lymphoma that’s not getting better with current treatments. The first purpose of this study is to check how safe glofitamab is alone and then combination it with some usual cancer medicines. It will be focused on how well this combination works on blood cancer. The goal is to understand if this treatment could help young patients with such tough types of blood cancer.

    DenmarkFranceGermanyItalySpain
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    AustriaBelgiumFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Continued cancer treatment study for osimertinib users

    The ROSY-T study is a follow-up study of patients who used a drug called osimertinib. Researchers will evaluate the effectiveness of treatment with this drug and decide whether patients need to continue using it. This study is open-label, which means that every patient will receive the drug. During treatment, doctors will pay close attention to your health to make sure the medicine is safe.

    FrancePolandUnited Kingdom
  • Durvalumab and chemotherapy in advanced biliary tract cancer treatment

    This study is testing the effectiveness and safety of durvalumab, a biological drug, combined with various gemcitabine-based chemotherapy regimens in patients with advanced biliary tract cancers (aBTC). The trial will include four periods: a screening phase, a treatment phase of up to 8 cycles of chemotherapy with durvalumab, a maintenance phase with durvalumab alone or in combination with chemotherapy, and a follow-up phase for safety and survival. Patients will receive durvalumab via intravenous infusion every 3 or 4 weeks, along with chemotherapy every 3 or 2 weeks for a maximum of 8 cycles. The study’s primary goal is to observe any severe adverse events possibly related to the treatment. Secondary goals include measuring overall survival, response rate, progression-free survival, and other factors.

    FranceGermanyItalySpain
  • Lung cancer treatment study: tarlatamab’s safety & effects

    This medical study is investigating how safe and effective a new lung cancer medication, tarlatamab, is for adults. The study involves multiple doses of tarlatamab either alone or with other treatments and aims to find the best dose with the fewest side effects. Participants will receive tarlatamab through a vein. The main goals are to see how the body processes the drug, how well it treats lung cancer, and monitor any side effects. The study is not blinded, meaning everyone knows what treatment is given.

    AustriaFranceGermanyNetherlandsPolandSpainUnited Kingdom
  • Testing new combination treatments for kidney cancer

    This study, part of a broader research project exploring new treatments for kidney cancer, specifically Renal Cell Carcinoma (RCC). These treatments include different combinations of drugs from among the listed: Pembrolizumab, Favezelimab, Belzutifan, Lenvatinib, Quavonlimab and Vibostolimab. The research comprises two stages: a safety assessment stage and an efficacy evaluation stage. In the first stage, the study aims to determine the safety and tolerability of a few different drug combinations. The study will monitor any unexpected adverse health events and track the number of participants who may need to discontinue the treatment due to health concerns. In the second stage, the study will assess the effectiveness of these various drug combinations and identify any uncomfortable or unwelcome effects. Additionally, researchers will observe how many participants can continue the treatment without experiencing adverse effects.

    FranceHungaryNetherlandsPolandSpainUnited Kingdom
  • Testing new potential drug for blood cancer treatment

    This study investigates the potential treatment BMS-986158 for Myelofibrosis, a type of blood cancer. The research is designed to assess the safety and effectiveness of BMS-986158, both as a standalone treatment and in combination with other drugs like Ruxolitinib or Fedratinib. The study is divided into two main parts: the first part examines the combination of BMS-986158 with either Ruxolitinib or Fedratinib, while the second part evaluates the BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone. The primary objectives include ensuring the safety of the treatment and observing its ability to prevent the progression of cancer and spleen-related issues.

    FranceGermanyGreeceItalyPolandRomaniaSpain
  • Exploring new potential treatment for advanced solid tumor patients

    This study is testing a drug named JDQ443 (Opnurasib) on patients with advanced kinds of tumors who also have a specific genetic mutation known as KRAS G12C. The purpose is to figure out how safe the drug is, how high a dose people can take without severe side effects, and how well the drug works to shrink the tumors. Patient’s reactions to the drug and any side effects researchers have will be carefully noted. Patients will get different amounts of the drug alone, a combination with other treatments (TNO155-Batoprotafib and Tislelizumab). Additionally, an assessment will be made regarding the peak concentration of the drug in the patient’s blood and the time it takes to reach that level. In patients receiving an additional drug, tislelizumab, testing will be conducted to determine whether this combination elicits any immune-related responses.

    BelgiumDenmarkFranceGermanyItalyNetherlandsSpain
  • Study on new medicine and immune drugs for hard-to-treat tumors

    The safety and efficacy of a new drug, Zanzalintinib (XL092) is currently evaluated in investigation in a trial designed for individuals with inoperable solid tumors or those that have metastasized. The drug may be administered as a standalone treatment or in combination with other medications designed to stimulate the immune system’s response to combat cancer. The initial phase focuses on determining the appropriate dosage for Zanzalintinib. Subsequently, the trial aims to assess the effectiveness of Zanzalintinib and companion drugs in reducing tumor size and enhancing survival rates. Throughout the study, potential adverse reactions to the drug will also be monitored. During the second stage, the evaluation of Zanzalintinib will be expanded to analyze outcomes in patients with specific cancer types. The objective is to investigate whether the drug leads to a slower progression of cancer and a reduction in tumor size for individuals with these particular types of cancer.

    AustriaBelgiumFranceGermanyItalyPolandSpainUnited Kingdom
  • Medicine combination study for various advanced cancers

    This trial explores the effects of a two-drug combo on various advanced cancers, focusing on the best tolerable doses. Adults with advanced solid tumors, like lung cancer, gastric cancer, and sarcoma, are included. The trial involves the drugs BI 907828 and ezabenlimab, aiming to shrink tumors. Participants receive treatments in cycles, with regular health checks to assess benefits and monitor side effects. When the study began, some participants were given an extra medicine called BI 754111. However, the use of BI 754111 was discontinued because data from another study revealed that it did not provide any additional benefits. The study seeks to offer new hope for those facing advanced cancers by testing this novel treatment approach.

    BelgiumFranceGermanyHungaryNetherlandsSpainUnited Kingdom
  • Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyPolandPortugalRomaniaSlovakiaSpain
  • Testing a new drug for advanced cancer or lymphomas

    In this research, the researchers are testing a new drug called OSE-279 that might help fight cancer. The researchers are looking for people who have very advanced forms of cancer, like tumors or lymphoma, which are not responding to other treatments. This study has two main parts. First, it is important to try to find the right dose of the drug that is safe but also effective. Then, the researchers expand the trial with more people to see how well it works. Main measurements are how much the cancer shrinks (responses), how long it stays like that (response duration), to evaluate the drug’s effectiveness.

    BelgiumFrance
  • Research on using new therapy for treating advanced tumors

    This research is about a new medicine named INCB123667. It may help people who have serious cancers that have spread to other parts of the body. The trial has two parts. Part 1 will find out the best dose to use and if it causes any side effects. Part 2 will see if the medicine helps shrink the cancer cells. Doctors will check for side effects the first time the medicine is given. If side effects are severe, the medicine dose will be reduced. The timing of when the drug is given may also need to be changed. Doctors will measure the highest amount of the drug in the blood and how fast it reaches this level. They’ll also see how long it stays in the system and how quickly the body gets rid of it. Successful treatment would mean the cancer stops growing or shrinks.

    FranceItalyNetherlandsUnited Kingdom

See more clinical trials in other cities in France:

.